KIRREL1: A Potential Drug Target and Biomarker (G55243)

Target Name: KIRREL1

NCBI ID: G55243

KIRREL1: A Potential Drug Target and Biomarker

KIRREL1, also known as KIRREL1A, is a gene that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique expression patterns and subcellular localization in neural cells make it an attractive target for drug developers. In this article, we will discuss the research on KIRREL1, its potential drug target status, and its potential as a biomarker for various diseases.

Research on KIRREL1

KIRREL1 was first identified in the course of a screening experiment for gene expression in neurodegenerative diseases. The screening experiment identified a gene that was highly expressed in the brains of individuals with Alzheimer's disease, a neurodegenerative disease. This gene was later found to encode a protein known as KIRREL1.

Subcellular localization of KIRREL1

KIRREL1 is a protein that is expressed in various cell types of the brain, including neurons and glial cells. However, its localization to specific cell types is not well understood. Researchers have used various techniques, such as immunofluorescence microscopy and biochemical assays, to localize KIRREL1 to specific cell types in the brain. These studies have shown that KIRREL1 is primarily expressed in neurons and glial cells in the brain, and is not present in other cell types.

Potential drug target status

KIRREL1's unique subcellular localization and its expression in neurodegenerative diseases make it an attractive target for drug developers. Studies have shown that KIRREL1 interacts with various proteins, including the protein huntingtin-1 (HN1), a protein that is known to play a role in the development and progression of neurodegenerative diseases.

In addition, KIRREL1 has also been shown to interact with the protein T-cell antigen 4 (TCA4), a protein that is known to promote the growth and survival of cancer cells. This interaction between KIRREL1 and TCA4 suggests that KIRREL1 may be a potential drug target for cancer.

Potential as a biomarker

KIRREL1 may also have the potential as a biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique expression patterns and subcellular localization in neural cells make it an attractive target for diagnostic biomarkers.

For example, KIRREL1 has been shown to be highly expressed in various types of cancer, including breast, ovarian, and colorectal cancer. This suggests that KIRREL1 may be a potential biomarker for cancer. Additionally, KIRREL1 has also been shown to be highly expressed in neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. This suggests that KIRREL1 may be a potential biomarker for these diseases.

Conclusion

In conclusion, KIRREL1 is a gene that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique subcellular localization and expression patterns in neural cells make it an attractive target for drug developers. Further research is needed to fully understand its potential as a drug target and biomarker.

Protein Name: Kirre Like Nephrin Family Adhesion Molecule 1

Functions: Required for proper function of the glomerular filtration barrier. It is involved in the maintenance of a stable podocyte architecture with interdigitating foot processes connected by specialized cell-cell junctions, known as the slit diaphragm (PubMed:31472902). It is a signaling protein that needs the presence of TEC kinases to fully trans-activate the transcription factor AP-1 (By similarity)

More Common Targets